Domestic production of medical isotope Mo-99 moves a step closer

May 14, 2013
From left, Los Alamos scientists Roy Copping, Sean Reilly, and Daniel Rios. Copping examines the Buchi Multivapor P-12 Evaporator, and Reilly and Rios are at the Agilent Technologies Cary 60 UV-Vis Spectrometer.

(Phys.org) —Today, Los Alamos National Laboratory announced that for the first time, irradiated uranium fuel has been recycled and reused for molybdenum-99 (Mo-99) production, with virtually no losses in Mo-99 yields or uranium recovery. This demonstrates the viability of the separation process, as well as the potential for environmentally- and cost-friendly fuel recycling. Medical isotope production technology has advanced significantly now that scientists have made key advances in separating Mo-99 from an irradiated, low-enriched uranium (LEU) solution.

Low-enriched uranium as a source of Mo-99

(Tc-99m) is the most commonly used medical isotope today, accounting for about 50,000 medical imaging procedures daily in the United States. Tc-99m is derived from the parent isotope Mo-99, predominantly produced from the fission of -235 in highly enriched uranium targets (HEU) in aging foreign reactors. The North American supply of Tc-99m was severely disrupted when the Chalk River in Canada experienced an outage several years ago.

The 's Global Threat Reduction Initiative (GTRI) implements the long-standing U.S. policy to minimize and eliminate the use of HEU in civilian applications. In support of this objective, GTRI is working with U.S. commercial entities and the U.S. national laboratories to develop a diverse set of non-HEU-based technologies to produce Mo-99 in the United States.

Pressure-rated sample containment vessels were designed, fabricated and rigorously tested prior to use for uranium fuel sample irradiation.

The U.S. national laboratories aid GTRI's programmatic mission by conducting research and development, engineering and design support, and demonstrations. Toward this goal, GTRI has been working with Los Alamos to ensure its technical expertise is available to support GTRI's commercial partners, including Morgridge Institute for Research-SHINE Medical Technologies (MIR-SHINE), which proposes to use a to produce Mo-99 from a mildly acidic LEU solution.

The technical demonstration

In support of MIR-SHINE's Mo-99 production efforts, researchers at Los Alamos have successfully proven the technical viability of the initial stage of Mo-99 recovery from LEU solution through a direct scaled-down demonstration of the proposed industrial process.

To undertake the necessary experimental validation, Los Alamos researchers developed methodologies for preparing and analyzing uranium sulfate fuel, safely containing the fuel during irradiation at a Los Alamos Neutron Accelerator Science (LANSCE) facility and performing chemical flow-sheet testing using a separation apparatus applicable to both low and high levels of radiation.

A view of the Buchi Multivapor P-12 Evaporator, apparatus that can be used in the preparation of the uranium sulfate fuel.

With a short half-life of 2.7 days, Mo-99 is a high specific-radioactivity isotope. At production scale, the post-fission solution will contain only a very small concentration of Mo-99. Unlike traditional HEU-based processes, the challenge is to recover this material from a vast excess of LEU and leave the uranium in the same chemical form to allow for recycling.

The team found that nearly all of the uranium could be recovered after Mo-99 separations were performed. The LEU fuel that passed through the column separation process was irradiated again, and then once more the fission-generated Mo-99 was separated in high yield. When the same fuel was irradiated a third time, there was still no observable loss in the subsequent Mo-99 recovery. The results confirm the viability of both the Mo-99 separation process and recycling, which can lower operating costs and minimize waste generation.

Capability development and future plans

Los Alamos has a long tradition of producing radioisotopes for medical, industrial, environmental, national security and research applications. The Los Alamos team has now developed a wide suite of new capabilities and is poised to serve the GTRI mission for present and future applications.

Explore further: New microscope collects dynamic images of the molecules that animate life

add to favorites email to friend print save as pdf

Related Stories

Europe-US deal to curb highly enriched uranium use

Mar 26, 2012

Three of the world's top suppliers of medical isotopes on Monday announced plans to work toward phasing out the use of highly enriched uranium in the production process under a deal with the United States.

Cyclotrons could alleviate medical isotope shortage

Jun 07, 2010

The most widely used medical radioisotope, Technetium-99m (Tc-99m), is essential for an estimated 70,000 medical imaging procedures that take place daily around the world. Aging reactors, production intermittencies and threats ...

New drug for use in bone scans approved

Feb 01, 2011

The FDA has approved a New Drug Application (NDA) from the National Cancer Institute (NCI), part of the National Institutes of Health, for a new strength of a previously approved drug, Sodium Fluoride F18, for use in bone ...

Nuclear medicine: a vital but troubled industry

Mar 25, 2012

Life begins at 40, but not for a small and ageing fleet of nuclear reactors vital for millions of life-saving medical procedures each year and using material that could go in an atomic bomb.

Recommended for you

Cooling with molecules

Oct 22, 2014

An international team of scientists have become the first ever researchers to successfully reach temperatures below minus 272.15 degrees Celsius – only just above absolute zero – using magnetic molecules. ...

User comments : 0